Vertex Pharmaceuticals Inc banner

Vertex Pharmaceuticals Inc
DUS:VX1

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
DUS:VX1
Watchlist
Price: 412.65 EUR 0.21%
Market Cap: €49.2B

Intrinsic Value

The intrinsic value for Vertex Pharmaceuticals Inc (VX1) under the Base Case is 377.76 EUR. Compared with the current market price of 412.65 EUR, the stock appears Overvalued by 8% .

Intrinsic value calculated using DCF
€377.76

Do our valuations actually work? See backtest results .

VX1 Intrinsic Value
377.76
Overvaluation 8%
Intrinsic Value
Price €412.65
Monitor VX1
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value €302.21
Get notified when the price drops into your buy zone
Current Price €412.65
Intrinsic Value €377.76
Margin of Safety 20% €302.21
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Valuation History
Ask AI Assistant
What other research platforms think about VX1?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is VX1 valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Vertex Pharmaceuticals Inc.

Explain Valuation
Alternatives to VX1

Wall St Price Targets

Capital Returns

Competitive Landscape

Ownership

VRTX Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one VX1 stock?

The intrinsic value for Vertex Pharmaceuticals Inc (VX1) under the Base Case is 377.76 EUR.

Is VX1 stock undervalued or overvalued?

Compared with the current market price of 412.65 EUR, the stock appears Overvalued by 8% .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett